Mounjaro vs Ozempic After the 2026 Drug Tariff: Which Is Cheaper?
After July 31, 2026, Mounjaro will be ~$400/month cheaper than Ozempic due to the pharmaceutical tariff. Here's the full comparison and how to switch.
Starting July 31, 2026, Ozempic gets a tariff surcharge. Mounjaro doesn't. For the millions of Americans taking GLP-1 medications, the 2026 pharmaceutical tariff creates a clear financial winner — and it's not the market leader. Here's the complete comparison of Mounjaro vs Ozempic after the drug tariff takes effect, and exactly how to switch if the math makes sense for you.
The Bottom Line
| Factor | Ozempic | Mounjaro |
|---|---|---|
| Manufacturer | Novo Nordisk (Denmark) | Eli Lilly (USA) |
| Affected by 2026 tariff? | Yes — 100% tariff July 31 | No — exempt (US-made) |
| Current retail (monthly) | ~$968 | ~$1,069 |
| Projected retail Aug 2026 (likely) | ~$1,452 | ~$1,069 (unchanged) |
| Savings with Mounjaro (Aug 2026) | — | ~$383/month = $4,600/year |
After the tariff, Mounjaro flips from being slightly more expensive to being significantly cheaper than Ozempic.
Clinical Comparison: Are They the Same?
Not exactly, but close enough that most patients can switch safely.
| Dimension | Ozempic (Semaglutide) | Mounjaro (Tirzepatide) |
|---|---|---|
| Mechanism | GLP-1 receptor agonist | Dual GLP-1 + GIP agonist |
| FDA indication | Type 2 diabetes | Type 2 diabetes |
| Off-label use | Weight loss (common) | Weight loss (less common — Zepbound is the weight loss version) |
| A1C reduction (average) | 1.4-1.8% | 1.7-2.1% |
| Weight loss (52 weeks) | ~13 lbs average (6-7%) | ~15-22 lbs average (7-11%) |
| Dosing schedule | Once weekly injection | Once weekly injection |
| Dose range | 0.25, 0.5, 1, 2 mg | 2.5, 5, 7.5, 10, 12.5, 15 mg |
| Common side effects | Nausea, diarrhea, constipation | Nausea, diarrhea, constipation |
| Discontinuation rate (clinical trials) | 6-8% | 5-9% |
| FDA approval | 2017 | 2022 |
Mounjaro generally shows somewhat better A1C reduction and more weight loss in head-to-head clinical trials. For diabetes control, most patients can achieve the same or better results on Mounjaro.
Cost Comparison: Month-by-Month Through 2026
Without Insurance (Full Retail)
| Month | Ozempic | Mounjaro | Mounjaro Savings |
|---|---|---|---|
| April 2026 | $968 | $1,069 | -$101 (Mounjaro more expensive) |
| May 2026 | $968 | $1,069 | -$101 |
| June 2026 | $968 | $1,069 | -$101 |
| July 2026 | $968 | $1,069 | -$101 |
| Aug 2026 (tariff active) | $1,452 | $1,069 | +$383 |
| Sept 2026 | $1,452 | $1,069 | +$383 |
| ...continuing | $1,452 | $1,069 | +$383/month |
Annual impact after July 31: Mounjaro saves $4,596/year vs Ozempic.
With Insurance (Typical Copay)
| Scenario | Ozempic Copay | Mounjaro Copay | Mounjaro Advantage |
|---|---|---|---|
| Today | $25 | $25 | Same |
| Aug 2026 (likely) | $75 (tier bump) | $25 (no change) | $50/month |
| Aug 2026 (worst) | Coinsurance 20% of $1,452 = $290 | $25 | $265/month |
Insurance copays may increase for Ozempic as insurers shift it to a higher formulary tier or apply coinsurance instead of flat copay.
Why Mounjaro Is Exempt From the Tariff
The tariff applies to drugs imported into the US. Eli Lilly manufactures Mounjaro (and Zepbound, Trulicity, Emgality) at facilities in:
- Indianapolis, IN — Lilly's main US manufacturing campus
- Durham, NC — expanded facility for GLP-1 production
- Lebanon, IN — $3.7B expansion announced 2024 for tirzepatide
Because the drug is made in the US, it's not imported, so there's no tariff. This is true even though Eli Lilly is listed in Annex III of the proclamation — the company is subject to the proclamation's terms, but drugs they make in the US are exempt.
Ozempic, by contrast, is manufactured by Novo Nordisk in Kalundborg, Denmark (the primary global production site) and packaged/filled in Hillerød, Denmark. Every Ozempic pen sold in the US is imported. The 100% tariff applies to the wholesale import cost.
How to Switch From Ozempic to Mounjaro
Step 1: Talk to Your Doctor (Start in April-May 2026)
Switching isn't automatic — you need a new prescription. Your doctor will want to discuss:
- Clinical appropriateness — most Type 2 diabetes patients can switch, but your specific situation matters
- Side effect history — if you had severe GI side effects on Ozempic, starting Mounjaro at a low dose is important
- Weight loss goals — Mounjaro generally produces more weight loss; this may be a feature or a concern
- Current dose — you don't start Mounjaro at an equivalent high dose; titration required
Step 2: Check Your Insurance Formulary
Ask your insurer:
- Is Mounjaro on formulary?
- What tier is it on?
- Is there a prior authorization requirement?
- What's my estimated copay?
Many insurance plans cover both Ozempic and Mounjaro for diabetes. Some plans require "step therapy" — trying Ozempic first — but if you've already been on Ozempic, that requirement is met.
Step 3: Start at a Low Dose
Mounjaro starting dose is 2.5 mg weekly — this is considered a "titration dose" not intended for glycemic control. After 4 weeks, most patients move to 5 mg. From there, your doctor will adjust based on response.
Don't expect same-day equivalence: A patient on 1 mg Ozempic doesn't switch to 1 mg Mounjaro. The drugs aren't dose-equivalent.
Step 4: Monitor for 4-8 Weeks
Track:
- Blood glucose (fasting + postprandial)
- A1C at 12 weeks
- Side effects (nausea, GI symptoms)
- Weight changes
Most patients adjust well. If Mounjaro doesn't work for you, switching back to Ozempic is possible.
What About Zepbound vs Wegovy?
Zepbound and Wegovy are the weight-loss versions of Mounjaro and Ozempic respectively. Same situation:
| Factor | Wegovy | Zepbound |
|---|---|---|
| Manufacturer | Novo Nordisk (Denmark) | Eli Lilly (USA) |
| Tariff affected | Yes | No |
| Current retail | ~$1,349 | ~$1,086 |
| Likely retail Aug 2026 | ~$2,024 | ~$1,086 |
| Savings with Zepbound | — | ~$938/month = $11,250/year |
If you're taking Wegovy for weight loss and paying out of pocket, switching to Zepbound saves over $11,000/year after the tariff takes effect.
Will Insurance Force Me to Switch?
Possibly. Some insurers may respond to the tariff by:
- Moving Ozempic to a higher tier — increasing copay
- Requiring prior authorization — more paperwork
- Preferring Mounjaro as the formulary choice — making it the "easier" option
- Applying step therapy — requiring Mounjaro trial before Ozempic coverage
Insurers care about cost. If Mounjaro is $400/month cheaper, they have strong incentive to prefer it.
Other GLP-1 Alternatives
| Drug | Manufacturer | Tariff Status | Notes |
|---|---|---|---|
| Ozempic / Wegovy | Novo Nordisk (Denmark) | Affected | Market leader, imported |
| Mounjaro / Zepbound | Eli Lilly (USA) | Exempt | US-made, dual agonist |
| Trulicity | Eli Lilly (USA) | Exempt | Older GLP-1, weekly |
| Victoza / Saxenda | Novo Nordisk (Denmark) | Affected | Older, daily injection |
| Rybelsus (oral semaglutide) | Novo Nordisk (Denmark) | Affected | Oral form of Ozempic |
| Bydureon | AstraZeneca (USA) | Exempt | Older weekly, less effective |
For patients who want the exact same molecule (semaglutide) as Ozempic but with better tariff treatment — unfortunately, there's no US-made semaglutide option. The molecule is Novo Nordisk-proprietary.
What If Novo Nordisk Signs a Deal?
Novo Nordisk is reportedly in deal negotiations with the administration. If Novo signs a pricing deal, Ozempic/Wegovy may:
- Have the tariff waived entirely
- Get Most-Favored-Nation (MFN) reference pricing (meaning US price matches the lowest developed-world price — potentially LOWER than today)
- Have volume commitments that change US availability
If Novo signs a deal, the Mounjaro advantage could disappear — or even reverse (if MFN pricing on Ozempic drops below Mounjaro's price).
Recommendation: Have the switching conversation with your doctor now, but don't actually switch until you see whether Novo signs a deal. Monitor announcements through May-July 2026.
Frequently Asked Questions
Is Mounjaro's tariff exemption guaranteed?
Yes, as long as Eli Lilly continues to manufacture Mounjaro in the US. The exemption is based on country of manufacture, which is a contractual and operational fact. Eli Lilly has publicly committed to US manufacturing and is expanding (not reducing) US production.
Will Mounjaro run out due to demand surge?
Possibly. Mounjaro has had supply constraints in 2024-2025 due to demand. The tariff-driven shift from Ozempic could add further demand pressure. Eli Lilly's Lebanon, IN expansion (completing 2026) will add significant capacity, but short-term shortages are possible.
Can I get Mounjaro for weight loss?
Mounjaro is FDA-approved for Type 2 diabetes only. For weight loss, Zepbound (same molecule) is the approved formulation. Some doctors prescribe Mounjaro off-label for weight loss; insurance coverage varies.
What if I need the exact Ozempic pen format?
The pen delivery system is different between Ozempic and Mounjaro. If you have a strong preference, you can stay with Ozempic — but be prepared for the tariff-driven price increase.
Will compounded semaglutide escape the tariff?
Compounded semaglutide has been a gray-market alternative during Ozempic shortages. As of 2024, the FDA has limited compounding as Ozempic is no longer on the FDA shortage list. The legal status of compounded semaglutide is complex — consult a licensed pharmacist.
Conclusion
After July 31, 2026, Mounjaro will be approximately $400/month cheaper than Ozempic — a $4,600/year difference that's hard to ignore. Clinical effectiveness is comparable (and Mounjaro may be slightly better for A1C and weight loss). For most Type 2 diabetes patients paying out-of-pocket or with coinsurance, switching is worth serious consideration. Talk to your doctor early, monitor Novo Nordisk's deal negotiations, and use the calculator to see your specific price impact.